Comparison of Two Methods to Detect Publication Bias in Meta-analysis

Peters, Jaime; Sutton, Alex J.; Jones, David R.; Abrams, Keith R.; Rushton, Lesley

doi:10.1001/jama.295.6.676

Cited by 1,843 publications

(1,301 citation statements)

References 20 publications

Supporting

Mentioning

1,286

Contrasting

Unclassified

Order By: Relevance

“…A funnel plot was used to assess publication bias with respect to primary end points. However, because graphical evaluation can be subjective, we performed both Harbord 11 and Peters tests, 12 as formal statistical tests for publication bias. Statistical analyses were performed using STATA 12.0 statistical software (STATA Corp, College Station, TX).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared With Everolimus-Eluting Stents

Piccolo

Stefanini

Franzone

et al. 2015

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

Background-Although new-generation drug-eluting stents represent the standard of care among patients undergoing percutaneous coronary intervention, there remains debate about differences in efficacy and the risk of stent thrombosis between the Resolute zotarolimus-eluting stent (R-ZES) and the everolimus-eluting stent (EES). The aim of this study was to evaluate the safety and efficacy of the R-ZES compared with EES in patients undergoing percutaneous coronary intervention. Methods and Results-A systematic literature search of electronic resources was performed using specific search terms until September 2014. Random-effects meta-analysis was performed comparing clinical outcomes between patients treated with R-ZES and EES up to maximum available follow-up. The primary efficacy end point was targetvessel revascularization.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Recommended antiplatelet therapy in various trials is reported in Table 1. At 1-year follow-up, 78.9% of patients (6419/8138) were on dual-antiplatelet therapy (data available for 3 trials 11,12,15 ).…”

Section: What the Study Addsmentioning

confidence: 99%

Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared With Everolimus-Eluting Stents

Piccolo

Stefanini

Franzone

et al. 2015

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

show abstract

“…26,27 Despite its limitations, this method is widely used to assess publication bias. 28 We evaluated the methodological quality of individual studies using the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) checklist. 29 Individual studies were evaluated to assess whether each item on the STROBE checklist was met or not met.…”

Section: Resultsmentioning

confidence: 99%

High-risk consumers’ perceptions of preimplantation genetic diagnosis for hereditary cancers: a systematic review and meta-analysis

Quinn

Pal

Murphy

et al. 2012

Genetics in Medicine

View full text Add to dashboard Cite

Individuals carrying deleterious germline mutations placing them at increased risk for hereditary cancer syndromes (high-risk consumers) often have a great deal of fear and concern over transmitting mutations to their offspring, particularly conditions which are autosomal dominant. Preimplantation genetic diagnosis (PGD) is a procedure that can detect certain germline cancer predisposing mutations present in embryos. The objective of this review was to assess high-risk consumers' knowledge and perceptions of PGD for hereditary cancers. A systematic literature review was conducted through PubMed, Wiley Interscience, PsychInfo, and Cochrane Library databases to identify all articles assessing consumer knowledge and attitudes of PGD for hereditary cancer syndromes. We assessed heterogeneity and the robustness of findings through additional analyses according to study location, hereditary cancer type, and sample size. Thirteen articles remained eligible after the application of specific criteria. Results show a general low level of knowledge about PGD for hereditary cancers, moderate rates of acceptability among high-risk groups, and high levels of need for information about PGD. Individuals in specific risk groups such as those with a personal or family history of hereditary breast and ovarian cancer (HBOC) syndrome or familial adenomatous polyposis (FAP) may benefit from educational information from healthcare professionals about the use of PGD. 2012:14(2):191-200 Genet Med

show abstract

“…Cochran's Q-statistic and I 2 tests were also used to quantify heterogeneity among studies. A random-effect model (DerSimonian and Laird method) was applied for the evidence of significant heterogeneity (P < 0.05 or I 2 > 50%), whereas a fixed-effect model (Mantel-Haenszel method) was applied when there was no statistical heterogeneity (P > 0.05 or I 2 < 50%) (Peters et al, 2006;Jackson et al, 2012). One-way sensitivity analysis was carried out to assess if the results could have been affected significantly through sequential deletion of a single study in our meta-analysis to reflect the influence on the overall results.…”

Section: Resultsmentioning

confidence: 99%

AGER genetic polymorphisms increase risks of breast and lung cancers

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We evaluated the associations between three common polymorphisms in the AGER gene and the risks of breast (BC) and lung (LC) cancer using meta-analysis. A systematic electronic search of the literature was conducted to identify all potential correlation studies in Embase, Web of Science, Cochrane Library, CINAHL, PubMed, CISCOM, China BioMedicine (CBM), and China National Knowledge Infrastructure (CNKI) databases. Five case-control studies that investigated the correlation of AGER gene polymorphisms with BC and LC were included in the meta-analysis, representing 4337 subjects. An increased frequency of the AGER rs1800625 T>C polymorphism was observed in patients with either BC or LC. We found that the frequencies of AGER rs1800624 T>A and rs2070600 G>A variants were positively related to the risks of BC and LC under allelic models, but that these relationships were not detected under dominant models. Diseasestratified results under allelic models demonstrated that the frequencies of the AGER rs1800625 T>C and rs2070600 G>A polymorphisms were positively correlated with the susceptibility to LC, while the same correlations were not found in BC. Further subgroup analysis 17777 AGER SNPs and breast and lung cancers ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (4): 17776-17787 (2015) by genotyping method indicated that the rs1800624 T>A variant was associated with increased risks of BC and LC under a dominant model in both non-polymerase chain reaction-restriction fragment length polymorphism (non-PCR-RFLP) and PCR-RFLP subgroups. In conclusion, these data indicated that common polymorphisms in the AGER gene might increase the risks of BC and LC.

show abstract

Comparison of Two Methods to Detect Publication Bias in Meta-analysis

Abstract: Because of appropriate type I error rates and reduction in the correlation between the lnOR and its variance, the alternative regression test can be used in place of Egger's regression test when the summary estimates are lnORs.

Cited by 1,843 publications

References 20 publications

Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared With Everolimus-Eluting Stents

Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared With Everolimus-Eluting Stents

High-risk consumers’ perceptions of preimplantation genetic diagnosis for hereditary cancers: a systematic review and meta-analysis

AGER genetic polymorphisms increase risks of breast and lung cancers

Contact Info

Product

Resources

About